CARLSBAD, Calif., Jan. 4, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET) on Wednesday, January 11, 2023.
A live webcast of the presentation and Q&A session will be available on the Investors & Media section of the Ionis website. The replay will be available within 48 hours and will be archived for a limited time.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
| Last Trade: | US$28.40 |
| Daily Change: | 0.05 0.18 |
| Daily Volume: | 828,011 |
| Market Cap: | US$4.480B |
March 26, 2025 March 11, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
